Application of PEG-rhG-CSF in Breast Cancer Chemotherapy During COVID-19 Epidemic
Main Authors: | YU Mancheng, LI Xiang, XU Juan, WU Xinhong, FENG Yaojun |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2020-11-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0331.htm |
Similar Items
-
rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy
by: Chen, L., et al.
Published: (2022) -
Biological potency evaluation and characterization of rhG-CSF in pharmaceutical products Avaliação biológica da potência e caracterização de rhG-CSF em produtos farmacêuticos
by: Cristiane F. Codevilla, et al.
Published: (2004-01-01) -
Comparison of Two Regimens of RhG-CSF in Neutropenic Neonatal Septicemia: A Randomized Clinical Trial
by: Fatemeh Nayeri, et al.
Published: (2011-09-01) -
Comparison of Two Regimens of RhG-CSF in Neutropenic Neonatal Septicemia: A Randomized Clinical Trial
by: Fatemeh Nayeri, et al.
Published: (2011-09-01) -
A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer
by: Dongling Zou, et al.
Published: (2021-06-01)